Neoadjuvant Approaches in Hepatocellular Carcinoma: There's No Time Like the Present.
Joseph W FransesAndrew X ZhuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Hepatocellular carcinoma (HCC) remains a lethal malignancy and is an increasingly common cause of cancer death worldwide. Curative-intent surgical resection remains the standard of care for eligible patients, yet outcomes remain poor for many patients, with most patients experiencing recurrence in the 5 years after resection. There is currently significant interest in using locoregional and systemic therapies-in both the neoadjuvant and adjuvant settings-to increase the chance of cure. This review article appraises the existing literature and current clinical trial landscape of neoadjuvant therapies in HCC.
Keyphrases
- end stage renal disease
- rectal cancer
- clinical trial
- ejection fraction
- newly diagnosed
- prognostic factors
- chronic kidney disease
- lymph node
- locally advanced
- healthcare
- systematic review
- peritoneal dialysis
- palliative care
- randomized controlled trial
- type diabetes
- radiation therapy
- adipose tissue
- young adults
- insulin resistance
- metabolic syndrome
- single cell
- quality improvement
- weight loss